BPCP — Biopharma Credit Balance Sheet
0.000.00%
- £724.38m
- £720.16m
- $150.03m
- 80
- 81
- 71
- 93
Annual balance sheet for Biopharma Credit, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Cash and Short Term Investments | 193 | 94.7 | 121 | 86.2 | 5.62 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.208 | 10 | 19.8 | 20.3 | 31.8 |
Total Other Current Assets | |||||
Total Current Assets | 193 | 105 | 140 | 155 | 37.4 |
Long Term Investments | |||||
Total Assets | 1,388 | 1,371 | 1,364 | 1,357 | 1,200 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 9.39 | 6.34 | 26.3 | 15.9 | 17.9 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 9.39 | 6.9 | 26.6 | 15.9 | 17.9 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 1,379 | 1,364 | 1,337 | 1,341 | 1,182 |
Total Liabilities & Shareholders' Equity | 1,388 | 1,371 | 1,364 | 1,357 | 1,200 |
Total Common Shares Outstanding |